All In Biotech

Drug Trial Radar · NCT00966914

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Last checked: Nov 19, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

540

Actual

Start

Apr 2010

Primary completion

Apr 2013

Study completion Jun 2013

Sponsor

Sponsor type
Industry
Collaborators
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.
First posted
Aug 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tavocept is an investigational drug that is being developed to see if it can increase the survival of patients who are being treated with chemotherapy as well as to see if it can prevent or reduce side effects of chemotherapy. This research study is aimed at trying to find out if people with advanced adenocarcinoma of the lung who are treated with a standard combination of chemotherapy drugs will live longer if they are also treated with an investigational drug called "Tavocept." Another objective of this research study is to find out whether or not Tavocept helps to prevent or reduce side-effects like kidney damage, anemia, and nausea and vomiting that can occur with these drug combinations. The drug combinations that will be used in this research study will include either paclitaxel and cisplatin, or docetaxel and cisplatin. These drug combinations are approved to be used to treat people with advanced NSCLC. Every patient on this research study will be treated with standard chemotherapy for primary NSCLC in the form of either docetaxel or paclitaxel (these will be recommended by your research study doctor), which will be given in combination with cisplatin.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxelDrug

    Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks

  • Placebo in combination with cisplatin and docetaxel or paclitaxelDrug

    Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: throughout study

Locations

42 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Columbia, Missouri

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Germantown, Tennessee

  • Site not named

    Gabrovo, Bulgaria

  • Site not named

    Plovidv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Veliko Tarnovo, Bulgaria

  • Site not named

    Elblag, Poland

  • Site not named

    Szczecin, Poland

  • Site not named

    Torun, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Brasov, Romania

  • Site not named

    Bucharest, Romania

  • Site not named

    Cluj-Napoca, Romania

  • Site not named

    Craiova, Romania

  • Site not named

    Timișoara, Romania

  • Site not named

    Arkangelsk, Russia

  • Site not named

    Chelyabinsk, Russia

  • Site not named

    Krasnodar, Russia

  • Site not named

    Krasnodar Krai, Russia

  • Site not named

    Kursk, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Novosibirsk, Russia

  • Site not named

    Omsk, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Stavropol, Russia

  • Site not named

    Stavropol Krai, Russia

  • Site not named

    Tambov, Russia

  • Site not named

    Voronezh, Russia

  • Site not named

    Yaroslavl, Russia

  • Site not named

    Yekaterinburg, Russia

  • Site not named

    Chernihiv, Ukraine

  • Site not named

    Dnipropetrovsk, Ukraine

  • Site not named

    Donetsk, Ukraine

  • Site not named

    Kharkiv, Ukraine

  • Site not named

    Kherson, Ukraine

  • Site not named

    Sumy, Ukraine

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.